
CarthroniX receives strong proof-of-concept data indicating high efficacy of a novel anti-fibrotic drug candidate.
CarthroniX receives strong proof-of-concept data indicating high efficacy of a novel drug candidate in the bleomycin-induced model of pulmonary fibrosis.

CarthroniX recruits Hassan Serhan, Ph.D. to its advisory team.
Dr. Serhan is an executive consultant with deep expertise in spine and orthopaedics, technology evaluation and development and a seasoned professional in executive level management of large programs and complex corporate environments, has joined the CarthroniX team. With 15 years of experience identifying and growing disruptive orthopaedic technologies while at Johnson and Johnson, Hassan represents an excellent